manual-prevencion

MANUAL SEOM DE PREVENCIÓN Y DIAGNÓSTICO PRECOZ DEL CÁNCER 94 6. BIBLIOGRAFÍA 1. Ouaguia L, Mrizak D, Renaud S, Moralès O, Delhem N. Control of the inflammatory response mechanisms mediated by natural and induced regulatory T-cells in HCV-, HTLV-1-, and EBV-associated cancers. Mediators Inflamm. 2014;2014. 2. Brianti P, Flammineis E De, Mercuri SR. Review of HPV-related diseases and cancers Pina Brianti*, Eduardo De Flammineis, Santo Raffaele Mercuri Dermatology and Cosmetology Unit – San Raffaele Hospital – Milan – Italy. 3. Hellner K, Dorrell L. Recent advances in understanding and preventing human papillomavirus-related disease. F1000Research [Internet]. 2017;6(0):269. Available from: https://f1000research.com/articles/6-269/v1 4. Di Mario S, Basevi V, Lopalco PL, Balduzzi S, D’Amico R, Magrini N. Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV. J Immunol Res. 2015;2015. 5. Manuscript A, Carcinoma H. NIH Public Access. 2013;142(6):1264–73. 6. Abu-amara M, Bs MB, Feld JJ. Does Antiviral Therapy for Chronic Hepatitis B Reduce the Risk of Hepatocellular Carcinoma ? 2013;1(212). 7. Liu J, Yang H-I, Lee M-H, Lu S-N, Jen C-L, Batrla-Utermann R, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut [Internet]. 2013;1–10. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/24225939 8. Li Z-Q, Hu C-L, Yu P, Gu X-Y, Zhang J-J, Li H, et al. The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors. Clin Res Hepatol Gastroenterol [Internet]. 2017; Available from: http://linkinghub.elsevier.com/retrieve/pii/S2210740116302005 9. Rinaldi L, Di Francia R, Coppola N, Guerrera B, Imparato M, Monari C, et al. Hepatocellular carcinoma in HCV cirrhosis after viral clearance with direct acting antiviral therapy: preliminary evidence and possible meanings. Wcrj. 2016;3(3):e748. 10. Wirth TC, Manns MP. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(8):1467–74. 11. Aleman S, Rahbin N,WeilandO, Davidsdottir L, HedenstiernaM, Rose N, et al. A risk for hepatocellular carcinoma persists long- termafter sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57(2):230–6. 12. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52(3):833–44. 13. Dubrow R, Silverberg MJ, Park LS, Crothers K, Justice AC. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol [Internet]. 2012;24(5):506–16. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/22759737% 5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/22759737 14. Valencia Ortega ME. Tumores no definitorios de sida o el gigante dormido: Actualizaci??n. Enferm Infecc Microbiol Clin [Internet]. 2013;31(5):319–27. Available from: http://dx.doi.org/10.1016/j.eimc.2012.03.015 15. Gatell JM, D P, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, et al. New England Journal. October. 2008;339–54. 16. Marrazzo JM, Del Rio C, Holtgrave DR, Cohen MS, Kalichman SC, Mayer KH, et al. HIV Prevention in Clinical Care Settings: 2014 Recommendations of the International Antiviral Society-USA Panel. J Am Med Assoc [Internet]. 2014;312(4):390–409. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25038358 17. Luppi M, Barozzi P, Santagostino G, Trovato R, Schulz TF, Marasca R, et al. Molecular evidence of organ-related transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood [Internet]. 2000;96(9):3279–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11050015 18. Kaposi M, European E. Aposi ’ s. 2000;1027–38. 19. Brenner B, Rakowsky E, Katz A, Gutman H, Sulkes A, Schacter J, et al. Tailoring treatment for Classical Kaposi’s Sarcoma: Comprehensive clinical guidelines. Int J Oncol. 1999;14(6):1097–102. 20. Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: The EuroSIDA study. Cancer. 2004;100(12):2644–54. 21. Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, et al. Characterization and treatment of chronic active Epstein- Barr virus disease : a 28-year experience in the United States. 2016;117(22):5835–50. 22. Hislop AD. Early virological and immunological events in Epstein???Barr virus infection. Curr Opin Virol [Internet]. 2015;15(Im):75–9. Available from: http://dx.doi.org/10.1016/j.coviro.2015.08.002 23. Edlich RF, Arnette J a,Williams FM. Global epidemic of humanT-cell lymphotropic virus type-I (HTLV-I). J EmergMed [Internet]. 2000;18(1):109–19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10645850 24. Verdonck K, González E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007;7(4):266–81. 25. Azran I, Schavinsky-Khrapunsky Y, Aboud M. Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity. Retrovirology [Internet]. 2004;1:20. Available from: http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=514576&tool=pmcentrez&rendertype=abstract 26. Bazarbachi A, Plumelle Y, Ramos JC, Tortevoye P, Otrock Z, Taylor G, et al. Meta-analysis on the use of zidovudine and